研究方向：
1.寻找可用于肿瘤预防、诊断和治疗的新靶点，研究其在肿瘤发生发展中的信号转导通路及作用，发现人群易感标志物，并筛选靶标预防和治疗药物；
2.研究环境和食源性有毒有害物质的作用机制；
3.营养素过量时的毒代动力学及风险分析和估计。

研究进展：
1.评价十五种单体人参皂苷对人体五种主要P450酶活性的影响并与药物存在相互作用（PLoS ONE 2008; 3: e2697. *通讯作者）,该研究对于深入理解人参与药物的相互作用及临床优化联合用药具有重要意义。报道青蒿素及其衍生物对卵巢癌和肝癌的抗癌活性及构效关系并探讨其分子机制（J Cell Mol Med 2009 Jul;13:1358-70. *通讯作者; Clin Cancer Res 2008; 14: 5519-30. *通讯作者），已申请专利（专利申请号为200910049092.1），该研究为青蒿素类化合物作为新型抗癌(辅助)药物用于临床研究提供依据。
2.发现PALB2、FGFR2等基因的遗传多态性与中国汉族妇女乳腺癌易感性相关（Clin Cancer Res 2008; 14: 5931-37.*通讯作者; Carcinogenesis 2008 Dec;29:2341-6. *通讯作者）。发表关于维生素D和钙的摄入量对女性乳腺癌风险关系的Meta-analysis研究成果（Breast Cancer Res Treat. 2009 Oct 23. [Epub ahead of print]. *通讯作者），该研究成果表明维生素D和钙在乳腺癌预防中的重要作用，提示女性足量补充维生素D和钙可以降低乳腺癌发生风险，以上研究对于我国乳腺癌高危人群的筛选、乳腺癌的早期预防和治疗具有重要意义。

近期发表论文（2005-2009）：

1. Chen P, Hu P, Xie D, Qin Y, Wang F, and Wang H*. Meta-analysis of Vitamin D, Calcium and the Prevention of Breast Cancer. Breast Cancer Res Treat. 2009 Oct 23. [Epub ahead of print].
2. Chen T, Li M, Zhang R, and Wang H*. Dihydroartemisinin Induces Apoptosis and Sensitizes Human Ovarian Cancer Cells to Carboplatin Therapy. J Cell Mol Med. 2009，13(7):1358-70.
3. Lin S, Shen YH, Li HL, Yang XW, Chen T, Lu LH, Huang ZS, Liu RH, Xu XK, Zhang WD, Wang H*. Acylated iridoids with cytotoxicity from Valeriana jatamansi. J Nat Prod. 2009, 72(4):650-5.
4. Liang J, Chen P, Hu Z, Zhou X, Chen L, Li M, Wang Y, Tang J, Wang H* and Shen H. Genetic variants in fibroblast growth factor receptor 2 (FGFR2) contribute to susceptibility of breast cancer in Chinese women. Carcinogenesis. 2008, 29(12):2341-6.
5. Chen P, Liang J, Wang Z, Zhou X, Chen L, Li M, Xie D, Hu Z, Shen H, and Wang H*. Association of Common PALB2 Polymorphisms with Breast Cancer Risk: a Case-Control Study. Clin Cancer Res. 2008,14 (8): 5931-37.
6. Hou J, Wang D, Zhang R, and Wang H*. Experimental Therapy of Hepatoma with Artemisinin and Its Derivatives: In vitro and In vivo Activity, Chemosensitization, and Mechanisms of Action. Clin Cancer Res. 2008,14(17):5519-30.
7. Hao M, Zhao Y, Chen P, Huang H, Liu H, Zhang R, and Wang H*. Structure-Activity Relationship and Substrate-dependent Phenomena in Effects of Ginsenosides on Activities of Drug-metabolizing P450 Isozymes, PLoS ONE. 2008, 3(7):e2697.
8. Wang W, Wang H*, Rayburn ER, Zhao Y, Hill DL, Zhang R. 20(S)-25-methoxyl- dammarane-3β, 12β, 20-triol, a novel natural product for prostate cancer: activity in vitro and in vivo and mechanisms of action. Br J Cancer. 2008, 98(4):792-802.
9. Wang W, Rayburn ER, HaoM, Zhao Y, Hill DL, Zhang R, Wang H*. Experimental Therapy of Prostate Cancer with Novel Natural Product Anti-cancer Ginsenosides. Prostate. 2008, 68(8):809-819
10. Saif MW, Sellers S, Li M, Wang W, Cusimano L, Wang H*, Zhang R. A phase I study of bi-weekly administration of 24-h gemcitabine followed by 24-h irinotecan in patients with solid tumors. Cancer Chemother Pharmacol. 2007, 60(6):871-82.
11. Chen D, Zhang Z, Li M, Wang W, Li Y, Rayburn ER, Hill DL, Wang H*, Zhang R. Ribosomal protein S7 as a novel modulator of p53-MDM2 interaction: binding to MDM2, stabilization of p53 protein, and activation of p53 function. Oncogene. 2007, 26(35):5029-37.
12. Rayburn E, Wang W, Zhang R., Wang H*. Experimental therapy for colon cancer: anti-cancer effects of TLR9 agonism, combination with other therapeutic modalities, and dependence upon p53. Intl J Oncol. 2007, 30(6):1511-9.
13. He J, Zhou F, Shao K, Hang J, Wang H*, Rayburn E, Xiao Z, Lee SW. Xue Q, Feng X, Shi S, Zhang C, Zhang S. Overexpression of Pin1 in non-small cell lung cancer (NSCLC) and its correlation with lymph node metastases. Lung Cancer. 2007,56(1):51-58.
14. Wang W, Zhao Y, Rayburn E, Hill DL, Wang H*, Zhang R. In vitro anti-cancer activity and structure-activity relationships of natural products isolated from fruits of Panax ginseng. Cancer Chem Pharm. 2007,59(5):589-601.
15. Wang H*, Wang Y, Rayburn ER, Hill DL, Rinehart JJ, Zhang R. Dexamethasone as a chemosensitizer for breast cancer chemotherapy: Potentiation of the antitumor activity of adriamycin, modulation of cytokine expression, and pharmacokinetics. Intl J Oncol. 2007,30(4):947-53. (*Corresponding author)
16. Wang H*, Li M, Lin W, Wang W, Zhang Z, Rayburn E, Lu J, Chen D, Yue X, Shen F, Jiang F, He J, Wei W, Zeng X. Zhang R. Extracellular activity of cAMP-dependent protein kinase (ECPKA) as a biomarker for human cancer detection: distribution characteristics in a normal population and cancer patients. Can Epidem Biomarker Prev. 2007,16(4):789-95.
17. Li M, Zhang Z, Hill DL, Wang H*, Zhang R. Curcumin, a dietary component, has anti-cancer, chemosensitization and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3 kinase/mTOR/ETS2 pathway. Cancer Res. 2007,67(5):1988-96.
18. Zhao Y, Wang W, Rayburn E, Hill DL, Wang H*, Zhang R. Isolation, Structural Determination, and Evaluation of the Biological Activity of 20(S)-25-methoxyl- dammarane-3β, 12β, 20-triol [20(S)-25-OCH3-PPD], a Novel Natural Product from Panax notoginseng. Med Chem. 2007, 3:51-60.
19. Rayburn E, Wang W, Zhang Z, Li M, Zhang R, Wang H*. Experimental therapy of prostate cancer with an immunomodulatory oligonucleotide: effects on tumor growth, apoptosis, proliferation, and potentiation of chemotherapy. Prostate. 2006, 66(15):1653-63.
20. Wang Z, Wang H*, Rhie JK, Covey JM, Liang P, Wang S, Wang C, Hu Y, Prasad G, Nan L, Hill DL, Zhang R. Determination of desoxyepothilone B in nude mice plasma by liquid-liquid extraction and reversed-phase high-performance liquid chromatography. J Pharm Biomed Anal. 2006, 42(2):272-6.
21. LaCasse EC, Cherton-Horvat GG, Hewitt KE, Morris SJ, Kandimalla ER, Yu D, Wang H*, Wang W, Zhang R, Agrawal S, Gillard JW, Durkin JP. Preclinical characterization of AEG35156/GEM640, a second generation antisense oligonucleotide targeting XIAP. Clin Cancer Res. 2006,12(17):5231-41.
22. Wang H*, Rayburn E, Wang W, Kandimalla ER, Agrawal S, Zhang R. Immunomodulatory oligonucleotides as novel therapy for breast cancer: pharmacokinetics, in vitro and in vivo anti-cancer activity and potentiation of antibody therapy. Mol Cancer Therapeutics. 2006, 5(8):2106-14.
23. Zhang R and Wang H*. Antisense strategies for the development of novel cancer therapeutics. In: A.A. Adjei and J.K. Buolamwini, eds. Novel Anticancer Agents Strategies for Discovery and Clinical Testing. Elsevier Science, New York, NY. 2006, 193-206.
24. Li M, Wang H*, Hill DL, Stinson S, Veley K, Grossi I, Peggins J, Covey JM, Zhang R. Preclinical pharmacology of the novel antitumor agent adaphostin, a tyrphostin analog that inhibits bcr/abl. Cancer Chemother Pharm, 2006; 57(5):607-614. Rayburn ER, Wang H, Zhang R. Antisense-based cancer therapeutics: are we there yet? Expert Opinion on Emerging Drugs. 2006, 11(2):337-52.
25. Wang H*, Rayburn E, Wang W, Kandimalla ER, Agrawal S, Zhang R. Chemotherapy and chemosensitization of non-small cell lung cancer with a novel immunomodulatory oligonucleotide targeting TLR9. Mol Cancer Ther. 2006, 5(6):1585-92.
26. Zhang R and Wang H*. Antisense strategies for the development of novel cancer therapeutics. In: A.A. Adjei and J.K. Buolamwini, eds. Novel anticancer agents strategies for discovery and clinical testing. Elsevier Science, New York, NY. 2006, 193-206.
27. Zhang Z, Wang H*, Li M, Agrawal S, Zhang R. Stabilization of E2F1 protein by MDM2 through the E2F1 ubiquitination pathway. Oncogene. 2005, 24(48):7238-47.
28. Zhang Z, Wang H*, Li M, Rayburn E, Agrawal S, Zhang R. Novel MDM2 p53-independent functions identified through RNA silencing technologies. Ann N Y Acad Sci. 2005, 1058:205-14.
29. Li M, Zhang Z, Hill D, Chen X, Wang H*, Zhang R. Genistein, a dietary isoflavone, down-regulates the MDM2 oncogene at both transcriptional and posttranslational levels. Cancer Res. 2005, 65(18):8200-8.
30. Zhang Z, Li M, Rayburn E, Hill DL, Zhang R, Wang H*. Oncogenes as novel targets for cancer Therapy (part I): Growth factors and protein tyrosine kinases. Am J Pharmacogenomics. 2005, 5(3):173-90.
31. Zhang Z, Li M, Rayburn E, Hill DL, Zhang R, Wang H*. Oncogenes as novel targets for cancer therapy (part II): Intermediate signaling molecules. Am J Pharmacogenomics. 2005, 5(4):247-57.
32. Zhang Z, Li M, Rayburn E, Hill DL, Zhang R, Wang H*. Oncogenes as novel targets for cancer therapy ((Part III): Transcription. Am J Pharmacogenomics. 2005, 5(5):327-38.
33. Zhang Z, Li M, Rayburn E, Hill DL, Zhang R, Wang H*. Oncogenes as novel targets for cancer therapy (Part IV): Regulators of the cell cycle, DNA damage repair and apoptosis. Am J Pharmacogenomics. 2005, 5(6):397-407.
34. Wang H*, Rayburn E, Zhang R. Synthetic oligodeoxynucleotides containing deoxycytidyl-deoxyguanosine dinucleotides (CpG ODNs) and modified analogs as novel anti-cancer therapeutics. Curr Pharm Des. 2005,11(22):2889-907.
35. Wang H*, Li M, Rhie JK, Hockenbery DM, Covey JM, Zhang R, Hill DL. Preclinical pharmacology of 2-Methoxyantimycin A compounds as novel antitumor agents. Cancer Chemother Pharm. 2005, 56(3):291-8.
36. Wang H*, Wang Z, Wang S, Li M, Nan L, Rhie JK, Covey JM, Zhang R, Hill DL. Preclinical pharmacology of Epothilone D, a novel tubulin-stabilizing antitumor agent. Cancer Chemother Pharm. 2005, 56(3):255-60.
37. Posey JA, Wang H*, Hamilton J, Delgrosso A, Zhang R, Freda T, Zamboni WC. Phase-I dose escalation and sequencing study of docetaxel and continuous infusion topotecan in patients with advanced malignancies. Cancer Chemother Pharmacol. 2005, 56(2):182-8.
38. Zhang R, Wang H*, Agrawal S. Novel antisense anti-MDM2 mixed-backbone oligonucleotides: Proof of principle, in vitro and in vivo activities, and Mechanisms. Curr Cancer Drug Targets. 2005, 5(4):43-50.
39. Rayburn E, Zhang R, He J, Wang H*. MDM2 and human malignancies: Expression, clinical pathology, prognostic markers, and implications for chemotherapy. Curr Cancer Drug Targets. 2005, 5(1):27-42.
40. Rayburn E, Wang H*, He J, Zhang R. RNA silencing technologies in drug discovery and target validation. Letters in Drug Design and Discovery. 2005, 2(1):1-18.
41. Rayburn E, Wang W, Zhang R, and Wang H*. Antisense approach in drug discovery and development. Prog Drug Res. 2005, 63:227-74.